Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Beluga Health vs Nova MD

Beluga Health
Graded #431

Lower grade

vs+10.799999999999997
Nova MD
Graded #187

Higher grade

The verdict

Nova MD takes it — 66.6/100 to 55.8/100.

Nova MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Nova MD is a telehealth platform offering compounded semaglutide and tirzepatide on 1-month and 3-month plans, with an uncommon explicit microdose program for both molecules.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNova MD +22
45
67
Dose & formulationNova MD +24
40
64
Clinical oversightNova MD +6
76
82
Labs & monitoringBeluga Health +8
62
54
FulfillmentNova MD +4
64
68
Contract termsEven
55
55
Beluga Health · left barNova MD · right bar

The numbers

MetricBeluga HealthNova MD
WeighScore55.8/10066.6/100
GradeCC
Scorecard rank#431#187
SemaglutideNot disclosed$175/mo (compounded)
TirzepatideNot disclosed$225/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Beluga Health

Graded #431 · C

Strengths

  • Supports GLP-1 care with compounded semaglutide and tirzepatide
  • Board-certified providers and a 50-state medical infrastructure
  • LegitScript certified with SOC 2 and ISO 27001 security
  • Pharmacies follow FDA/USP standards with third-party batch testing
  • Powers many DTC brands as a turnkey telehealth backbone

Where it loses points

  • White-label B2B group, not a direct consumer-facing service
  • Offers compounded, not FDA-approved branded, GLP-1s
  • No public consumer pricing for the GLP-1 offering
  • Cited among nationwide groups tied to FDA telehealth GLP-1 scrutiny
  • Care quality varies by the consumer brand using the platform
Nova MD

Graded #187 · C

Strengths

  • On-page pricing published for all four SKUs (semaglutide and tirzepatide, 1- and 3-month)
  • $125/mo semaglutide and $199/mo tirzepatide 3-month plans rank among the cheapest in the market
  • $50 off first tirzepatide order shown publicly
  • Explicit microdose / low-dose program for both semaglutide and tirzepatide
  • Broader menu (sermorelin, NAD+, glutathione, enclomiphene) for longevity alongside GLP-1

Where it loses points

  • Legal entity name and state of incorporation not disclosed
  • Compounding pharmacy not named — only 'accredited facilities'
  • LegitScript certification not confirmed (only 'Licensed US Providers' claims)
  • Per-state availability not listed
  • Compounded only — no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard